Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acadia Pharmaceutica
(NQ:
ACAD
)
16.29
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acadia Pharmaceutica
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 27, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 26, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 12, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Earnings Scheduled For May 5, 2021
May 05, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Stocks Drop On May 5 As Inflation Rises And Growth Slows
May 05, 2021
Stocks finished mostly lower, with the S&P 500 up just 7 bps, while the Qs fell by almost 35 bps. The index had been higher nearly all day and fell sharply going into the final hour of trading.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
May 05, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
NASDAQ:ACAD Investor Notice: Lawsuit Alleges Misleading Statements by ACADIA Pharmaceuticals Inc
May 04, 2021
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investor, who purchased NASDAQ:ACAD shares, filed a lawsuit against ACADIA Pharmaceuticals Inc over alleged Securities Laws violations.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
May 04, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
SHAREHOLDER ALERT: Law Offices of Timothy L. Miles Is Investigating Acadia Pharmaceuticals Inc. on Behalf of Investors
May 02, 2021
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders
Via
EIN Presswire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Cramer Gives His Opinion On Lemonade, Pinterest And More
May 02, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he still likes Lemonade Inc (NYSE: LMND). Investors will have to wait a long time for the value of the stock...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2021
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid...
Via
Benzinga
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
April 30, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
April 29, 2021
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 28, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
April 28, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACAD
April 27, 2021
From
Rosen Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
April 27, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
April 26, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders
April 23, 2021
From
Robbins LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
April 23, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 23, 2021
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 22, 2021
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
April 22, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
April 21, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
April 21, 2021
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
April 20, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 20, 2021
Gainers Artelo Biosciences (NASDAQ:ARTL) stock rose 5.26% to $1.2 during Tuesday's after-market session. This security traded at a volume of 43.6K shares come close, making up...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.